Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody

Guozheng Liu, Shuping Dou, Ali Akalin, Mary Rusckowski, Philip Streeter, Leonard D. Shultz, Dale L. Greiner

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: We previously demonstrated MORF/cMORF pretargeting of human islets and betalox 5 cells (a human beta cell line) transplanted subcutaneously in mice with the anti-human islet antibody, HPi1. We now compare pretargeting with direct targeting in the beta cell transplant model to evaluate the degree to which target/non-target (T/NT) ratios may be improved by pretargeting. Methods: Specific binding of an anti-human islet antibody HPi1 to the beta cells transplanted subcutaneously in mice was examined against a negative control antibody. We then compared pretargeting by MORF-HPi1 plus 111In-labeled cMORF to direct targeting by 111In-labeled HPi1. Results: HPi1 binding to betalox5 human cells in the transplant was shown by immunofluorescence. Normal organ 111In backgrounds by pretargeting were always lower, although target accumulations were similar. More importantly, the transplant to pancreas and liver ratios was, respectively, 26 and 10 by pretargeting as compared to 9 and 0.6 by direct targeting. Conclusions: Pretargeting greatly improves the T/NT ratios, and based on the estimated endocrine to exocrine ratio within a pancreas, pretargeting may be approaching the sensitivity required for successful imaging of human islets within this organ.

Original languageEnglish (US)
Pages (from-to)645-651
Number of pages7
JournalNuclear Medicine and Biology
Volume39
Issue number5
DOIs
StatePublished - Jul 2012

Fingerprint

Islets of Langerhans
Transplants
Antibodies
Pancreas
Fluorescent Antibody Technique
islet cell antibody
Cell Line
Liver

Keywords

  • Anti-human islet antibody
  • Islet cell imaging
  • Pretargeting
  • T/NT ratios

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody. / Liu, Guozheng; Dou, Shuping; Akalin, Ali; Rusckowski, Mary; Streeter, Philip; Shultz, Leonard D.; Greiner, Dale L.

In: Nuclear Medicine and Biology, Vol. 39, No. 5, 07.2012, p. 645-651.

Research output: Contribution to journalArticle

Liu, Guozheng ; Dou, Shuping ; Akalin, Ali ; Rusckowski, Mary ; Streeter, Philip ; Shultz, Leonard D. ; Greiner, Dale L. / Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody. In: Nuclear Medicine and Biology. 2012 ; Vol. 39, No. 5. pp. 645-651.
@article{770235d5c2794c30b828f9025b54c7cb,
title = "Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody",
abstract = "Introduction: We previously demonstrated MORF/cMORF pretargeting of human islets and betalox 5 cells (a human beta cell line) transplanted subcutaneously in mice with the anti-human islet antibody, HPi1. We now compare pretargeting with direct targeting in the beta cell transplant model to evaluate the degree to which target/non-target (T/NT) ratios may be improved by pretargeting. Methods: Specific binding of an anti-human islet antibody HPi1 to the beta cells transplanted subcutaneously in mice was examined against a negative control antibody. We then compared pretargeting by MORF-HPi1 plus 111In-labeled cMORF to direct targeting by 111In-labeled HPi1. Results: HPi1 binding to betalox5 human cells in the transplant was shown by immunofluorescence. Normal organ 111In backgrounds by pretargeting were always lower, although target accumulations were similar. More importantly, the transplant to pancreas and liver ratios was, respectively, 26 and 10 by pretargeting as compared to 9 and 0.6 by direct targeting. Conclusions: Pretargeting greatly improves the T/NT ratios, and based on the estimated endocrine to exocrine ratio within a pancreas, pretargeting may be approaching the sensitivity required for successful imaging of human islets within this organ.",
keywords = "Anti-human islet antibody, Islet cell imaging, Pretargeting, T/NT ratios",
author = "Guozheng Liu and Shuping Dou and Ali Akalin and Mary Rusckowski and Philip Streeter and Shultz, {Leonard D.} and Greiner, {Dale L.}",
year = "2012",
month = "7",
doi = "10.1016/j.nucmedbio.2011.12.001",
language = "English (US)",
volume = "39",
pages = "645--651",
journal = "International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody

AU - Liu, Guozheng

AU - Dou, Shuping

AU - Akalin, Ali

AU - Rusckowski, Mary

AU - Streeter, Philip

AU - Shultz, Leonard D.

AU - Greiner, Dale L.

PY - 2012/7

Y1 - 2012/7

N2 - Introduction: We previously demonstrated MORF/cMORF pretargeting of human islets and betalox 5 cells (a human beta cell line) transplanted subcutaneously in mice with the anti-human islet antibody, HPi1. We now compare pretargeting with direct targeting in the beta cell transplant model to evaluate the degree to which target/non-target (T/NT) ratios may be improved by pretargeting. Methods: Specific binding of an anti-human islet antibody HPi1 to the beta cells transplanted subcutaneously in mice was examined against a negative control antibody. We then compared pretargeting by MORF-HPi1 plus 111In-labeled cMORF to direct targeting by 111In-labeled HPi1. Results: HPi1 binding to betalox5 human cells in the transplant was shown by immunofluorescence. Normal organ 111In backgrounds by pretargeting were always lower, although target accumulations were similar. More importantly, the transplant to pancreas and liver ratios was, respectively, 26 and 10 by pretargeting as compared to 9 and 0.6 by direct targeting. Conclusions: Pretargeting greatly improves the T/NT ratios, and based on the estimated endocrine to exocrine ratio within a pancreas, pretargeting may be approaching the sensitivity required for successful imaging of human islets within this organ.

AB - Introduction: We previously demonstrated MORF/cMORF pretargeting of human islets and betalox 5 cells (a human beta cell line) transplanted subcutaneously in mice with the anti-human islet antibody, HPi1. We now compare pretargeting with direct targeting in the beta cell transplant model to evaluate the degree to which target/non-target (T/NT) ratios may be improved by pretargeting. Methods: Specific binding of an anti-human islet antibody HPi1 to the beta cells transplanted subcutaneously in mice was examined against a negative control antibody. We then compared pretargeting by MORF-HPi1 plus 111In-labeled cMORF to direct targeting by 111In-labeled HPi1. Results: HPi1 binding to betalox5 human cells in the transplant was shown by immunofluorescence. Normal organ 111In backgrounds by pretargeting were always lower, although target accumulations were similar. More importantly, the transplant to pancreas and liver ratios was, respectively, 26 and 10 by pretargeting as compared to 9 and 0.6 by direct targeting. Conclusions: Pretargeting greatly improves the T/NT ratios, and based on the estimated endocrine to exocrine ratio within a pancreas, pretargeting may be approaching the sensitivity required for successful imaging of human islets within this organ.

KW - Anti-human islet antibody

KW - Islet cell imaging

KW - Pretargeting

KW - T/NT ratios

UR - http://www.scopus.com/inward/record.url?scp=84862784188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862784188&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2011.12.001

DO - 10.1016/j.nucmedbio.2011.12.001

M3 - Article

C2 - 22316614

AN - SCOPUS:84862784188

VL - 39

SP - 645

EP - 651

JO - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology

JF - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology

SN - 0969-8051

IS - 5

ER -